About Proacta
Proacta is a publicly listed company based in Warsaw (Poland) founded in 2007. The company has since been acquired. Proacta offers products and services including AI/ML Services, Software Solutions, and Medtech Products. Its focus areas include HealthTech, Life Sciences Tech, Biostatistics and Life Sciences. Its legal entity is PROACTA SPÓŁKA AKCYJNA. Its competitors include Rhino Health, Genozip, Beth Bioinformatics, Biostatech and Neurosnap and 2 more.
Company details
Provider of bioinformatics solutions for the health sector. The company offers DATABION, a multifunctional analytical platform used to collect, process and analyze data from genetic tests in combination with traditional medical data.
- Headquarters Warsaw, Poland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website proacta.pl
- Social LinkedIn Facebook Instagram
- Legal Name Proacta S.A.
- Annual Revenue$2.57 M (USD)196.86as on Dec 31, 2025
- Net Profit$160.25 K (USD)0as on Dec 31, 2025
- EBITDA$1.58 M (USD)0as on Dec 31, 2025
Products & Services of Proacta
Proacta offers a comprehensive portfolio of products and services, including AI/ML Services, Software Solutions, and Medtech Products.
Advanced models for predicting healthcare outcomes and data analysis
Tools supporting clinical decisions and patient data management
Innovative solutions for improving medical processes and care efficiency
IPO & Listings of Proacta
Proacta is a publicly listed company on the NEWCONNECT with ticker symbol PAC in Poland, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Jul 2017
- Listed onNEWCONNECT: PAC
- Listed entityProacta S.A.
- Exchange sectorTechnology services
- ISINPLBTEVL00019
- Share price1.57 PLN (-0.63% on the day) · 2026-10-02
- Market capitalisation184,357,295.00 PLN
- Price to earnings75.5
- EPS (diluted, trailing year)0.02 PLN
- Volume (last session)7,766
Financials of Proacta
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 9.2M PLN | 575,680 PLN | 5.7M PLN |
| 2024 | 3.1M PLN | -15.4M PLN | -2.9M PLN |
| 2023 | 647,670 PLN | -990,680 PLN | -972,980 PLN |
| 2022 | 1.3M PLN | -2.2M PLN | -1.5M PLN |
| 2021 | 985,300 PLN | -235,600 PLN | -191,860 PLN |
Detailed financial statements for Proacta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Proacta
2 dated milestones of Proacta across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Proacta is founded.
- IPO Lists on the stock exchange (IPO).
Competitors of Proacta
Proacta has 7 listed competitors in our database. They include Rhino Health, Genozip, Beth Bioinformatics, Biostatech and Neurosnap, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rhinohealth.com | 2016 | United States | – | – | Federated computing solutions are provided for AI and data collaboration. | |
| genozip.com | 2016 | Hong Kong, China | – | – | Provides efficient lossless compression software for genomic data files and institutions. | |
| bethbio.com | 2018 | Hong Kong, China | – | – | Vaccines are developed using AI and bioinformatics for genomic analytics. | |
| biostatech.com | 2012 | – | – | – | Bio-statistics consultancy services are provided to researchers and institutions. | |
| neurosnap.ai | 2022 | United States | – | – | Provides code-free tools for bioinformatics tasks like protein folding and molecular docking. | |
| tinybio.cloud | 2023 | New York, United States | – | – | AI chat tools for bioinformatics questions, data analysis, and code debugging. | |
| marbyt.com | 2021 | Murcia, Spain | – | – | Provides customized bioinformatics tools and support for research in biotechnology sectors. |
Detailed competitors of Proacta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Proacta (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Proacta
Complete news archive for Proacta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proacta
Proacta was founded in 2007.
Proacta is headquartered in Warsaw, Poland.
Annual revenue of Proacta is $2.57M as on Dec 31, 2025.
Provider of bioinformatics solutions for the health sector. The company offers DATABION, a multifunctional analytical platform used to collect, process and analyze data from genetic tests in combination with traditional medical data.
Proacta's top competitors include Biostatech, Beth Bioinformatics and Rhino Health.
Proacta offers AI/ML Services, Software Solutions, and Medtech Products.
Yes, Proacta is publicly traded on NEWCONNECT under the ticker symbol PAC.
Proacta operates through Proacta Spółka Akcyjna.